Samalizumab
Based on 1 publication(s) in Google Scholar
Samalizumab (ALXN 6000) is a humanized monoclonal antibody that specifically binds to CD200 and blocks its ligation to the CD200 receptor (CD200R). Samalizumab can be used for multiple myeloma and B-cell chronic lymphocytic leukemia research.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度 : 99.94%
- CAS 番号: 1073059-33-2
- 分子量:144.84 kDa
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
MedChemExpress(MCE)の使用を引用している文献 Samalizumab
More
生物活性
製品説明
Isotype
Human IgG2 kappa
Recommend Isotype Controls
Species Reactivity
Human
IC50 & Target
CD220/Insulin Receptor
体外実験
Samalizumab is rationally engineered with an Ig G2/G4 constant region to minimize effector function and preserve immune cell subsets. Samalizumab is a first-in-class, recombinant humanized anti-CD200 mAb, engineered to ablate effector function, that specifically binds to the immune checkpoint CD200, blocks receptor engagement and signaling and antagonizes CD200-driven immune suppression, thereby mount an anti-tumor immune response[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
臨床実験
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
遺伝子ID
アクセッション番号
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Human IgG4 kappa
アプリケーション
ELISA, FACS, Functional assay
Verified Bioactivity
-
Immobilized CD200 Protein (His Tag), Human can bind Samalizumab. The EC50 for this effect is 1.53 ng/mL.
化学情報
-
CAS 番号 1073059-33-2
-
性状 Liquid
-
分子量 144.84 kDa
-
Color Colorless to light yellow
-
SMILES
[Samalizumab]
-
別名
ALXN 6000
-
輸送条件
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Int Immunopharmacol
Monocytes from patients with myelodysplastic syndrome inhibit natural killer cell-mediated antitumor function through the CD200/CD200R pathway. [Abstract]2025 Apr 16:152:114394. PMID: 40049088
純度とドキュメンテーション
-
データシート (257 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
参考文献
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)